Gossamer Bio (GOSS) Expected to Announce Earnings on Thursday

Gossamer Bio (NASDAQ:GOSS) is expected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $7.5260 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Gossamer Bio Price Performance

Shares of Gossamer Bio stock opened at $0.58 on Thursday. The stock has a market capitalization of $134.25 million, a price-to-earnings ratio of -0.84 and a beta of 2.08. The business has a 50-day moving average of $2.23 and a 200 day moving average of $2.60. Gossamer Bio has a 12 month low of $0.33 and a 12 month high of $3.87.

Analysts Set New Price Targets

GOSS has been the subject of a number of research reports. Wedbush restated a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research note on Thursday, January 22nd. Royal Bank Of Canada raised Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Thursday, January 22nd. Finally, Barclays lowered Gossamer Bio from an “overweight” rating to an “underweight” rating in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $6.67.

Institutional Trading of Gossamer Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its position in shares of Gossamer Bio by 36.0% during the 4th quarter. Invesco Ltd. now owns 478,909 shares of the company’s stock worth $1,485,000 after buying an additional 126,823 shares during the last quarter. Corient Private Wealth LLC lifted its position in Gossamer Bio by 19,123.7% in the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after acquiring an additional 3,825,879 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Gossamer Bio by 52.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock valued at $74,000 after acquiring an additional 8,239 shares in the last quarter. Beacon Pointe Advisors LLC purchased a new position in shares of Gossamer Bio during the fourth quarter worth about $34,000. Finally, XTX Topco Ltd increased its position in shares of Gossamer Bio by 66.1% during the fourth quarter. XTX Topco Ltd now owns 456,329 shares of the company’s stock worth $1,415,000 after purchasing an additional 181,547 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.